Simon Schwartz Navarro Senior scientist and advisor with specific interest in Nanomedicine and Advanced Therapies applied to unmet clinical needs. I am also acting as strategy coordinator to facilitate programs and initiatives that foster innovation in new treatments and diagnostic tools. Institutions of which they are part Main researcher Clinical Biochemistry, Drug Delivery & Therapy (CB-DDT) Vall Hebron Institut de Recerca Cap de Secció Bioquímica Cross-departmental services LinkedIn Twitter Orcid Email Simon Schwartz Navarro LinkedIn Twitter Orcid Email Institutions of which they are part Main researcher Clinical Biochemistry, Drug Delivery & Therapy (CB-DDT) Vall Hebron Institut de Recerca Cap de Secció Bioquímica Cross-departmental services Senior scientist and advisor with specific interest in Nanomedicine and Advanced Therapies applied to unmet clinical needs. I am also acting as strategy coordinator to facilitate programs and initiatives that foster innovation in new treatments and diagnostic tools.
Currently acting as Strategy director of biobanking and bioresources at Vall d'hebron Campus. President of the European Society of Nanomedicine and Executive Board member of the International Society of Nanomedicine. Former director general of the Blood and Tissue Banc of Catalonia. Former director of CIBBIM-Nanomedicine. Former scientific associate director of CIBER-BBN and coordinator of technology transfer. Former director assistance of translational research at VHIR. H-index of 40, with more that 115 high impact publications and 17 transferred patents. Co-founder of 3 biotech companies (i.e, Bsure Medical ltd). Science Advisor of the European Nanomedicine Characterization Laboratory (EU-NCL). Member of the editorial Board of Precision Nanomedicine, J. Nanotechnology and of J. of Nanotheranostics. Former editorial Board member of Eur. J. Nanomedicine and Nanomedicine-NBM.
Projects Nuevos transductores para KRAS y BRAF en cáncer colorectal con inestabilidad de microsatélites esporádico y hereditario: diferencias de activación según el entorno molecular tumoral IP: Simon Schwartz Navarro Collaborators: - Funding agency: Instituto de Salud Carlos III Funding: 54000 Reference: FI07/00002 Duration: 01/01/2008 - 31/12/2011 Validación Funcional de dianas terapéuticas y nuevas nanomedicinas en modelos in vitro e in vivo de cáncer colorectal IP: Simon Schwartz Navarro Collaborators: - Funding agency: Fundació Institut de Recerca HUVH Funding: 13000 Reference: PRED/IR-HUVH/13/2007 Duration: 01/01/2008 - 31/12/2011 Investigación y desarrollo de productos y tecnologías de diagnóstico-pronóstico y aplicaciones terapéuticas en la enfermedad neoplásica. IP: Simon Schwartz Navarro Collaborators: Investigación y desarrollo de productos y tecnologías de diagnóstico-pronóstico y aplicaciones terapéuticas en la enfermedad neo, Manuel Armengol Carrasco, Eloy Espín Basany Funding agency: Oncnosis Pharma, AIE Funding: 249000 Reference: CENIT/02/2006 Duration: 01/04/2006 - 31/12/2009 Nuevos transductores para Kras y BRAF en cáncer colorectal con inestabilidad de microsálites esporádico y hereditario: diferencias de activación según el entorno molecular tumoral. IP: Simon Schwartz Navarro Collaborators: Eloy Espín Basany Funding agency: Instituto de Salud Carlos III Funding: 97580 Reference: PI050304 Duration: 01/01/2006 - 31/12/2008 Pagination First page « Previous page ‹ … Page 7 Page 8 Current page 9 Page 10 Page 11 Next page › Last page »
